Last reviewed · How we verify

Doxycycline Hyclate Enteric-Coated Capsules — Competitive Intelligence Brief

Doxycycline Hyclate Enteric-Coated Capsules (Doxycycline Hyclate Enteric-Coated Capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline antibiotic. Area: Infectious Disease.

marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Doxycycline Hyclate Enteric-Coated Capsules (Doxycycline Hyclate Enteric-Coated Capsules) — The Third Xiangya Hospital of Central South University. Doxycycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Doxycycline Hyclate Enteric-Coated Capsules TARGET Doxycycline Hyclate Enteric-Coated Capsules The Third Xiangya Hospital of Central South University marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
DoxyPEP DoxyPEP Chinese University of Hong Kong marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
Tobramycin once a day Tobramycin once a day Oslo University Hospital marketed Aminoglycoside antibiotic Bacterial 30S ribosomal subunit
Gentamicin - three days Gentamicin - three days Murdoch Childrens Research Institute marketed Aminoglycoside antibiotic Bacterial 30S ribosomal subunit
inhaled tobramycin inhaled tobramycin Seattle Children's Hospital marketed Aminoglycoside antibiotic Bacterial 30S ribosomal subunit
Minocycline HCl Minocycline HCl OraPharma marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
Amikacin Injection Amikacin Injection Murdoch Childrens Research Institute marketed Aminoglycoside antibiotic Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tetracycline antibiotic class)

  1. OraPharma · 2 drugs in this class
  2. Vyne Therapeutics Inc. · 2 drugs in this class
  3. Beijing Tiantan Hospital · 1 drug in this class
  4. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
  5. Darier · 1 drug in this class
  6. Edward Lain, MD · 1 drug in this class
  7. Generic (originally Pfizer) · 1 drug in this class
  8. Galderma R&D · 1 drug in this class
  9. Johns Hopkins University · 1 drug in this class
  10. Chinese University of Hong Kong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Doxycycline Hyclate Enteric-Coated Capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/doxycycline-hyclate-enteric-coated-capsules. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: